Levoxa

Levofloxacin, the active ingredient in Levoxa, is a fluoroquinolone antibiotic presented as an oral tablet for systemic use. It is prescribed to treat susceptible bacterial infections in adults and children when indicated by a healthcare professional.

GNH USA supplies Levoxa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU Good Manufacturing Practice and providing reliable, traceable supply chains for essential medicines. The company’s quality assurance team ensures each batch meets stringent regulatory standards before export.

Levoxa (levofloxacin) is employed to treat infections caused by susceptible bacteria across several organ systems.

- Urinary Tract Infection: eliminates susceptible uropathogens, leading to resolution of dysuria, frequency and flank pain. - Community‑Acquired Pneumonia: provides bacterial eradication in the lower respiratory tract, improving cough, fever and oxygenation. - Skin and Soft Tissue Infection: targets Gram‑negative and Gram‑positive organisms, promoting healing of cellulitis and wound infections. - Acute Bacterial Prostatitis: penetrates prostatic tissue to eradicate infection, relieving pelvic pain and urinary symptoms.

Levoxa may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild stomach upset often transient. - Diarrhea: loose stools that may be self‑limiting. - Headache: mild to moderate intensity. - Dizziness: sensation of light‑headedness. - Insomnia: difficulty falling or staying asleep. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Tendon rupture: sudden pain and loss of function, especially in the Achilles. - QT interval prolongation: may lead to cardiac arrhythmias. - Clostridioides difficile infection: severe colitis with watery diarrhea. - Severe allergic reaction: anaphylaxis with swelling, breathing difficulty. - Peripheral neuropathy: numbness or tingling in extremities. - Hepatic toxicity: elevated liver enzymes or jaundice.

Before prescribing Levoxa, clinicians should evaluate patient factors and follow safety measures. - Assess renal function: dose adjustment may be required in patients with impaired clearance. - Review allergy history: avoid use in individuals with known hypersensitivity to fluoroquinolones. - Monitor for tendon symptoms: discontinue if pain, swelling or inflammation of tendons occurs. - Evaluate cardiac risk: caution in patients with prolonged QT interval or taking other QT‑prolonging drugs. - Consider CNS effects: avoid concomitant use with drugs that lower seizure threshold. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Levoxa can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: markedly reduce levofloxacin absorption. - Iron or zinc supplements: decrease oral bioavailability when taken simultaneously. - Warfarin: may potentiate anticoagulant effect, increasing INR. - Theophylline: levofloxacin can raise plasma theophylline levels, risking toxicity. - Cyclosporine: increased cyclosporine concentrations may occur.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen): heightened risk of central nervous system stimulation. - Corticosteroids: combined use may increase risk of tendon rupture. - Rifampin: may lower levofloxacin plasma levels, reducing antibacterial activity.